19 recruiting, 16 unknown, 9 completed, 5 not yet recruiting. 25 Phase 2, 7 Not applicable, 5 Phase 3, 3 Phase 1.
Follow Chemoradiotherapy: new trials by email Literature Review of Chemoradiotherapy trials Research Report on Chemoradiotherapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Multidimensional Study Designed to Develop a Methodological Framework Based on MRI Data to Predict Pathological Complete Response (pCR) in Patients With Locally Advanced Rectal Cancer After Neoadjuvant Treatment questionnaire completion - Rectal Cancer, Chemoradiotherapy | Not yet recruiting | Institut du Cancer de Montpellier - Val d'Aurelle | 115 | 2026-10-01 | 2026-09-14 | |
| SHR-1701 for Induction and Consolidation Therapy in Unresectable Stage III Non-Small Cell Lung Cancer SHR-1701 combined with platinum-doublet chemotherapy induction therapy, SHR-1701 consolidation therapy, Platinum-doublet chemotherapy - NSCLC Stage III, SHR-1701 | Phase 2 | Not yet recruiting | Fudan University | 84 | 2026-07-01 | 2026-06-02 |
| Ensartinib After Chemoradiotherapy in Stage III ALK-Mutated NSCLC Ensartinib 225mg, Placebo Ensartinib 225mg - NSCLC Stage III, Ensartinib | Phase 2 | Not yet recruiting | Shanghai Pulmonary Hospital, Shanghai, China | 45 | 2025-12-01 | 2025-11-19 |
| A Study of QL1706 Combined With Chemotherapy Induction on Sequential Immunotherapy Consolidation in Patients With Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy QL1706 (bispecific antibody targeting PD-1 and CLTA-4) - Limited-stage Small Cell Lung Cancer (LS-SCLC), Chemoradiotherapy | Phase 2 | Recruiting | Shanghai Chest Hospital | 28 | 2025-10-23 | 2026-06-11 |
| Consolidation of Toripalimab and Capecitabine After Chemoradiotherapy in ESCC toripalimab, capecitabine - Esophageal Cancer, Chemoradiotherapy | Phase 3 | Recruiting | Sun Yat-sen University | 242 | 2025-09-10 | 2026-04-21 |
| SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC PD-1 inhibitor based immunotherapy - Rectal Cancer, Rectal Adenocarcinoma | Phase 2 | Recruiting | Ruijin Hospital | 104 | 2025-09-05 | 2025-09-30 |
| Clinical Study of Thiopegfilgrastim for Preventing Bone Marrow Suppression in Thoracic Tumor Chemoradiotherapy Mecapegfilgrastim injection, Oral or short-acting granulocyte-stimulating agents - Myelosuppression, Thoracic Neoplasms | Phase 2 | Recruiting | Affiliated Hospital of Nantong University | 30 | 2025-08-01 | 2025-12-11 |
| Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma Neoadjuvant immunochemotherapy, Surufatinib Administration, Concurrent Chemotherapy - Toripalimab, Surufatinib | Phase 2 | Recruiting | Sun Yat-sen University | 69 | 2025-07-20 | 2025-11-17 |
| US Radiomics in Advanced Cervical Cancer Radiomic Analysis of Ultrasound Images - Uterine Cervical Neoplasms, Locally Advanced Cervical Cancer | Completed | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 220 | 2025-03-25 | 2025-05-22 | |
| Application of Intelligent Care Systems in Radiation Therapy: Enhancing Patient Safety and Reducing Anxiety Through System Optimization and Real-Time Blood Data Monitoring Real-Time Blood Data Monitoring System (Device/Software Integration), Enhanced Patient Education Materials (Behavioral/Educational Intervention), Internal Warning Signs and Alerts (Behavioral Intervention) - Radiation Therapy, Chemoradiotherapy | Not applicable | Not yet recruiting | Chung Shan Medical University | 100 | 2025-02-20 | 2025-02-20 |
| Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer. Radiation Therapy, Chemoradiotherapy, Consolidation Chemotherapy - Rectal Cancer, Total Neoadjuvant Treatment | Phase 2 / Phase 3 | Recruiting | National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos | 400 | 2025-01-06 | 2026-05-11 |
| Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer Chemotherapy, Immunotherapy, Angio-immuno kinase inhibitor - Toripalimab, Surufatinib | Phase 2 | Recruiting | Sun Yat-sen University | 47 | 2024-11-30 | 2026-03-03 |
| Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma Sintilimab - Esophageal Cancer, Chemoradiotherapy | Phase 2 | Recruiting | Zhejiang Cancer Hospital | 191 | 2024-06-01 | 2024-07-16 |
| Symptoms Burden in Lung Cancer Patients Undergoing Definitive Chemoradiotherapy: Insights From Electronic Patient-Reported Outcomes Electronic Patient-Reported Outcome Monitoring - Lung Cancer, Chemoradiotherapy | Recruiting | Qian Chu | 100 | 2024-06-01 | 2025-08-20 | |
| Sodium Glycididazole Reduces the Adverse Reactions of Concurrent Chemoradiotherapy sodium glycididazole - Chemoradiotherapy | Phase 2 | Unknown | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 40 | 2024-05-29 | 2024-10-31 |
| Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer Cardonilizumab, Chemoradiotherapy ±immunotherapy, Radical surgery - Esophageal Cancer, Immunotherapy | Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 60 | 2024-05-01 | 2025-05-30 |
| Toripalimab Combined With Definitive CCRT for LACC Patients Toripalimab, CCRT - Cervical Cancer, Chemoradiotherapy | Not applicable | Recruiting | Ruijin Hospital | 150 | 2024-02-02 | 2024-04-24 |
| Oral Microbiome is Associated With the Response to Chemoradiotherapy in Initial Inoperable Patients With Esophageal Squamous Cell Cancer regular chemoradiotherapy - Esophageal Squamous Cell Carcinoma, Chemoradiotherapy | Unknown | Anhui Provincial Hospital | 97 | 2023-07-01 | 2024-01-05 | |
| Whole-course Immunonutrition Combined With Chemoradiotherapy±ICIs for Local Advanced Patients With Inoperable Esophageal Squamous Cell Carcinoma Whole-course Immunonutrition Combined With Chemoradiotherapy±ICIs - Esophageal Squamous Cell Carcinoma, Chemoradiotherapy | Recruiting | Anhui Provincial Hospital | 70 | 2023-07-01 | 2023-12-26 | |
| Upfront Resection of Locally Advanced NSCLC Followed by Chemoradiotherapy Upfront resection - Locally Advanced Non-Small Cell Lung Cancer, Chemoradiotherapy | Not applicable | Unknown | The Netherlands Cancer Institute | 20 | 2023-04-01 | 2023-03-20 |
Showing 20 of 51. Sign in to see all of them.
Esophageal Neoplasms (9) · Esophageal Squamous Cell Carcinoma (8) · Rectal Neoplasms (7) · Uterine Cervical Neoplasms (7) · Carcinoma, Non-Small-Cell Lung (3) · Neoplasms (3) · Adenocarcinoma (2) · Head and Neck Neoplasms (2) · Small Cell Lung Carcinoma (2) · Stomach Neoplasms (2) · Anxiety Disorders (1) · Colonic Neoplasms (1) · Fatigue (1) · Febrile Neutropenia (1) · Gastrointestinal Neoplasms (1)
Neoplasms by Site (43) · Neoplasms (41) · Digestive System Diseases (26) · Digestive System Neoplasms (26) · Gastrointestinal Diseases (26) · Gastrointestinal Neoplasms (25) · Head and Neck Neoplasms (16) · Esophageal Diseases (15) · Carcinoma (11) · Neoplasms by Histologic Type (11) · Neoplasms, Glandular and Epithelial (11) · Carcinoma, Squamous Cell (8) · Colorectal Neoplasms (8) · Intestinal Diseases (8) · Intestinal Neoplasms (8)
Radiotherapy (9) · Chemoradiotherapy (8) · toripalimab (4) · Capecitabine (3) · Carboplatin (3) · Cisplatin (3) · nimotuzumab (3) · Albumin-Bound Paclitaxel (2) · Chemotherapy, Adjuvant (2) · Oxaliplatin (2) · Paclitaxel (2) · Platinum (2) · S 1 (combination) (2) · Surgical Procedures, Operative (2) · sintilimab (2)
Fudan University (8) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (7) · Sun Yat-sen University (3) · Anhui Provincial Hospital (2) · Ruijin Hospital (2) · Sichuan Cancer Hospital and Research Institute (2) · Affiliated Hospital of Nantong University (1) · Centre Hospitalier Universitaire, Amiens (1) · Chang Gung Memorial Hospital (1) · China Medical University Hospital (1) · Chinese Academy of Medical Sciences (1) · Chung Shan Medical University (1) · Corporacion Parc Tauli (1) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (1) · Fourth Affiliated Hospital of Guangxi Medical University (1)
China (36) · Taiwan (3) · France (2) · Germany (1) · India (1) · Italy (1) · Lithuania (1) · South Korea (1) · Spain (1)
Audrius Dulskas, PhD (1) · Camilla Culcasi (1) · Dong-Hoe Koo (1) · Dr. Supriya Chopra, MD (1) · Farkhad Manapov, PhD MD (1) · Haoping Xu (1) · Hui Liu (1) · Hui Liu, Professor (1) · Hui Qiu, Ph. D. (1) · Ji Zhu, MD (1) · Koen Hartemink, MD, PhD (1) · Kuaile Zhao (1) · Kuaile Zhao, doctor (1) · Laura Mora, Dr (1)
PMID 16437757, PMID 23008766, PMID 23058059, PMID 24070460, PMID 24748626, PMID 25629513, PMID 25825828, PMID 26099900, PMID 26309240, PMID 26608978, PMID 27536795, PMID 27637832, PMID 27642056, PMID 27863481, PMID 28535154, PMID 29019951, PMID 30025745, PMID 30216477, PMID 30565718, PMID 31877085, PMID 32563599, PMID 32728588, PMID 32918612, PMID 33417481, PMID 33505914, PMID 33538338, PMID 33707923, PMID 33946039, PMID 34843383, PMID 35143424, PMID 35280748, PMID 35574368, PMID 35764956, PMID 35958344, PMID 36604116, PMID 36990609, PMID 37046405, PMID 37150411, PMID 38710003, PMID 39972105, PMID 40123292, PMID 41531940, PMID 42492015, PMID 42639327